Protein kinase inhibitor

Bruton's Tyrosine Kinase (BTK) Inhibitors: Competitive Landscape, Global Markets and Pipeline Analysis (2020-2030)

Retrieved on:

Monday, March 16, 2020

Peripheral membrane proteins, Bruton's tyrosine kinase, Tyrosine kinase, Protein kinase inhibitor, BTK

DUBLIN, March 16, 2020 /PRNewswire/ -- The "Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, March 16, 2020 /PRNewswire/ -- The "Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The report provides the understanding of the unmet needs, market drivers and barriers of the Bruton's Tyrosine Kinase Inhibitors market.
Future competitive landscape of Bruton's Tyrosine Kinase (BTK) Inhibitors is estimated to be very strong.
Analysis of the current and future market competition in the global Bruton's Tyrosine Kinase Inhibitors market.

EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer

Retrieved on:

Friday, January 31, 2020

Today, we achieved a significant milestone towards our goal of making tucatinib available to patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, around the world, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.

Key Points:

Today, we achieved a significant milestone towards our goal of making tucatinib available to patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, around the world, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.
The MAA is based on data from the pivotal HER2CLIMB clinical trial, which compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.
Tucatinib has been granted orphan drug designation by the FDA for the treatment of breast cancer patients with brain metastases.
In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer, and in clinical development for metastatic colorectal cancer.

Global Colorectal Cancer Therapeutics Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Company and Eli Lilly and Company | Technavio

Retrieved on:

Wednesday, January 22, 2020

Pharmaceutical, Health, Oncology, RTT, Cancer, Protein kinase inhibitor, Clinical medicine, Bristol-Myers Squibb, Colorectal cancer, Life sciences, Merck, Antineoplastic drugs

View the full release here: https://www.businesswire.com/news/home/20200121005763/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20200121005763/en/
Technavio has announced its latest market research report titled global colorectal cancer therapeutics market 2019-2023.
The introduction of combination therapy and the development of small molecule kinase inhibitors is anticipated to boost the growth of the colorectal cancer therapeutics market.
Major Five Colorectal Cancer Therapeutics Market Companies:
Bristol-Myers Squibb Company operates its business through the BioPharmaceuticals segment.
Technavio has segmented the colorectal cancer therapeutics market based on the type and region.

Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

Retrieved on:

Thursday, January 9, 2020

PDGFRA, Protein kinase inhibitor, Tyrosine kinase inhibitors, Branches of biology, Oncogenes, Quinazolines, FIP1L1, Indoles, Gastrointestinal stromal tumor

The most common PDGFRA exon 18 mutation is the D842V mutation, which is resistant to all other approved therapies.

Key Points:

The most common PDGFRA exon 18 mutation is the D842V mutation, which is resistant to all other approved therapies.
Blueprint Medicines is dedicated to helping patients with PDGFRA exon 18 mutant GIST access treatment with AYVAKIT and providing robust support throughout their treatment journey.
As part of this commitment, Blueprint Medicines is introducing YourBlueprint, a patient support program that offers access and affordability solutions for individuals receiving AYVAKIT.
AYVAKIT (avapritinib) is a kinase inhibitor approved by the FDA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson

Retrieved on:

Thursday, January 2, 2020

Companies, Johnson & Johnson, Protein kinase inhibitor, Lung cancer, Health, Articles, Cyclacel

LEXINGTON, Mass., Jan. 2, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson*.Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception.

Key Points:

LEXINGTON, Mass., Jan. 2, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson*.Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception.
We look forward to collaborating with the Lung Cancer Initiative at Johnson & Johnson as we advance this important program.
If the Lung Cancer Initiative exercises the option on RV1162/PUR1800 and the portfolio of these kinase inhibitors, Pulmatrix is eligible for up to $91M in additional development and commercial milestones, as well as royalty payments.
*Johnson & Johnson Enterprise Innovation Inc. is the legal entity to the agreement.

Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer

Retrieved on:

Wednesday, December 18, 2019

The decision by the FDA to grant Breakthrough Therapy designation to tucatinib recognizes the urgent need for new medicines that can impact the lives of those with HER2-positive metastatic breast cancer.

Key Points:

The decision by the FDA to grant Breakthrough Therapy designation to tucatinib recognizes the urgent need for new medicines that can impact the lives of those with HER2-positive metastatic breast cancer.
This Breakthrough Therapy designation was based on data from the pivotal HER2CLIMB clinical trial, which compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.
Tucatinib has been granted orphan drug designation by the FDA for the treatment of breast cancer patients with brain metastases.
In addition, tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer.

Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of Medicine

Retrieved on:

Wednesday, December 11, 2019

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer (MBC) were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) and simultaneously published in the New England Journal of Medicine (NEJM).

Key Points:

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer (MBC) were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) and simultaneously published in the New England Journal of Medicine (NEJM).
The HER2CLIMB trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
HER2CLIMB is the first randomized pivotal trial completed to enroll patients with metastatic HER2-positive breast cancer who have untreated or previously treated and progressing brain metastases.
In addition, tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer.

Gossamer Bio Announces Data Presentations at the American Heart Association Scientific Sessions 2019

Retrieved on:

Monday, November 11, 2019

Biotechnology, General Health, Other Health, Health, Pharmaceutical, Hypertension, RTT, Pulmonary hypertension, Protein kinase inhibitor, PAH

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB002, the Companys inhaled PDGFR inhibitor for the treatment of pulmonary arterial hypertension (PAH), have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2019 being held November 16- 18 in Philadelphia, Pennsylvania.

Key Points:

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB002, the Companys inhaled PDGFR inhibitor for the treatment of pulmonary arterial hypertension (PAH), have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2019 being held November 16- 18 in Philadelphia, Pennsylvania.
Details for the AHA presentations are as follows:
Abstract Title: In Vivo Efficacy of a Novel, Inhaled PDGFRa/b Inhibitor, GB002, In The Rat Monocrotaline and Pneumonectomy Model of Pulmonary Arterial Hypertension
Abstract Title: GB002, A Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy in The Su5416 Hypoxia Rat Model Of Pulmonary Arterial Hypertension (PAH)
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191111005056/en/

Bcr-Abl Tyrosine Kinase Inhibitor - 2019 Pipeline Insight Report - ResearchAndMarkets.com

Retrieved on:

Wednesday, November 6, 2019

Biotechnology, Pharmaceutical, Health, Chemical compounds, Clinical medicine, Medicine, Pyrimidines, Philadelphia chromosome, ABL, Tyrosine kinase, Bcr-Abl tyrosine-kinase inhibitor, Protein kinase inhibitor, Chronic myelogenous leukemia, Bafetinib

The "Bcr-Abl Tyrosine Kinase Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Bcr-Abl Tyrosine Kinase Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Bcr-Abl Tyrosine Kinase Inhibitor development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
The report assesses the active Bcr-Abl Tyrosine Kinase Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference

Retrieved on:

Monday, November 4, 2019

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 10:20 a.m. Mountain Time.

Key Points:

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 10:20 a.m. Mountain Time.
The presentation will be webcast live and available for replay from Seattle Genetics website at www.seattlegenetics.com in the Investors section.
Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in peoples lives.
Tucatinib, a small molecule tyrosine kinase inhibitor, is in clinical trials for HER2-positive metastatic breast cancer and metastatic colorectal cancer.